| Literature DB >> 32812795 |
Ivo G Schoots1,2, Jelle O Barentsz3, Leonardo K Bittencourt4,5, Masoom A Haider6, Katarzyna J Macura7, Daniel J A Margolis8, Caroline M Moore9, Aytekin Oto10, Valeria Panebianco11, Mohummad M Siddiqui12, Clare Tempany13, Baris Turkbey14, Geert M Villeirs15, Jeffrey C Weinreb16, Anwar R Padhani17.
Abstract
The steadily increasing demand for diagnostic prostate MRI has led to concerns regarding the lack of access to and the availability of qualified MRI scanners and sufficiently experienced radiologists, radiographers, and technologists to meet the demand. Solutions must enhance operational benefits without compromising diagnostic performance, quality, and delivery of service. Solutions should also mitigate risks such as decreased reader confidence and referrer engagement. One approach may be the implementation of MRI without the use gadolinium-based contrast medium (bipara-metric MRI), but only if certain prerequisites such as high-quality imaging, expert interpretation quality, and availability of patient recall or on-table monitoring are mandated. Alternatively, or in combination, a clinical risk-based approach could be used for protocol selection, specifically, which biopsy-naive men need MRI with contrast medium (multiparametric MRI). There is a need for prospective studies in which biopsy decisions are made according to MRI without contrast enhancement. Such studies must define clinical and operational benefits and identify which patient groups can be scanned successfully without contrast enhancement. These higher-quality data are needed before the Prostate Imaging Reporting and Data System (PI-RADS) Committee can make evidence-based recommendations about MRI without contrast enhancement as an initial diagnostic approach for prostate cancer workup.Entities:
Keywords: MRI; PI-RADS; biopsy avoidance; biparametric MRI; dynamic contrast-enhanced; gadolinium contrast medium; multiparametric MRI; prostate cancer; risk stratification; unenhanced MRI
Mesh:
Year: 2020 PMID: 32812795 DOI: 10.2214/AJR.20.24268
Source DB: PubMed Journal: AJR Am J Roentgenol ISSN: 0361-803X Impact factor: 3.959